IndexBox sees UAE drug-loaded pellet demand rising 6-9% through 2035

IndexBox says the United Arab Emirates market for drug-loaded pellets is forecast to grow at a 6-9% CAGR from 2026 to 2035, with imports still supplying more than 80% of domestic demand.

The highest-stakes readers are pharmacy procurement heads, CFOs and medical directors. For Dubai providers, the issue is availability and reimbursement for modified-release oral medicines. For Abu Dhabi and the northern emirates, the same supply chain affects hospital formularies, chronic-disease prescribing and patient out-of-pocket costs. Dubai facilities operate under the Dubai Health Authority (DHA), Abu Dhabi and Al Ain under the Department of Health Abu Dhabi (DOH), and the northern emirates under the Ministry of Health and Prevention (MOHAP).

What IndexBox reported

The IndexBox report, updated on 25 August 2026, covers drug-loaded pellets used in oral solid dosage forms, including enteric-coated, sustained-release, immediate-release and multiparticulate formulations. IndexBox prices the single-user report at $4,000, with multi-user and enterprise licences listed at $5,600 and $6,800.

The core operating signal is that sustained-release and controlled-release pellet formulations account for about 45-55% of UAE demand, according to IndexBox. Immediate-release pellets hold about 20-25%. Enteric-coated pellets represent 10-15%. Oral solid dosage forms, mainly hard gelatin capsules filled with pellets, account for 60-70% of consumption.

• Import dependence: more than 80% of UAE supply.
• Main origins by volume: India 35-45%, China 20-30%, and Europe 20-25%.
• Typical lead times: 6-16 weeks, depending on origin and order complexity.
• Recommended safety stock cited by IndexBox: 8-12 weeks.

What this means for clinics and insurers

For clinics, drug-loaded pellets matter because they sit inside finished medicines used for controlled release, dose flexibility and age-appropriate administration. That affects chronic disease treatment, paediatric prescribing and geriatric care. A shortage of pellets can become a shortage of a capsule brand or generic product several weeks later.

IndexBox gives conventional immediate-release pellets a typical contract price of $200-500 per kg, equal to about AED 735-1,835 per kg at the UAE dirham dollar peg. Sustained-release and controlled-release pellets carry a 20-40% premium. Enteric-coated and high-specification multiparticulate pellets can exceed $800-1,200 per kg, or about AED 2,940-4,405 per kg. Clinical-trial-grade pellets can cost 2-3 times commercial-grade material.

Those numbers do not translate directly into the retail price of a medicine. The final patient price also depends on the registered product, pack size, dispensing margin, insurer tariff and formulary decision. A Dubai CFO should therefore ask pharmacy teams for four data points before accepting a substitution or tender proposal: the product registration status, the approved supplier, the landed cost in AED, and the insurer reimbursement status under the relevant network.

For insurers such as Daman, Thiqa and Sukoon, the practical question is whether modified-release products reduce repeat dispensing, adverse events or non-adherence enough to justify a higher acquisition cost. The answer will vary by molecule. Pharmacy benefit teams should compare a once-daily controlled-release product with the immediate-release alternative using claims data over a 90-day period, then check discontinuation and switching rates.

Regulatory and procurement watchpoints

IndexBox says regulatory approval timelines for modified-release pellet products in the UAE typically run 12-24 months. Operators should treat that as a working assumption for new products, then verify the pathway with the federal medicines authority and the emirate-level regulator that licenses the facility. Public verification should start with the MOHAP registered medical product directory, the DHA medical directory for Dubai, and DOH Abu Dhabi datasets such as Shafafiya where payer and provider checks are needed.

Procurement teams should also separate bulk pellet intermediates from finished registered medicines. Bulk inputs raise quality-assurance questions around certificates of analysis, stability data, dissolution testing and batch documentation. Finished products raise patient-facing questions around substitution, counselling and insurance approval.

The near-term implication is practical. Dubai pharmacies and clinic groups should map their controlled-release and enteric-coated oral medicines by supplier and remaining stock. Abu Dhabi providers should align pharmacy purchasing with DOH payer rules before switching brands. MOHAP-licensed providers in the northern emirates should confirm product registration before adding imported alternatives. For licensed pharmacy providers by emirate, use the UAE Open Healthcare Directory.